Reliable Rexall-A Compounding Pharmacy
FDA inspection history in San Francisco, California, 2016
- 1
- Form 483
Every document, by year
- Form 483
2016: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2016One Form 483, at San Francisco, California.
Cited most
Across all Reliable Rexall-A Compounding Pharmacy observations on file
- 21 CFR 211.84(d)(1)Testing and approval or rejection of components, drug product containers, and closures2
- 21 CFR 211.100(a)Written procedures; deviations1
- 21 CFR 211.125(a)Labeling issuance1
- 21 CFR 211.165(a)Testing and release for distribution1
- 21 CFR 211.166(a)Stability testing1
The complete Reliable Rexall-A Compounding Pharmacy file.
All 1 documents as original PDFs. For supplier audits, diligence and inspection prep.
Sites
San Francisco, California
One Form 483 · 2016 · 8 observations
Latest: Form 483, Mar 29, 2016 →
Documents
1 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2016-03-29 | 483 Form 483 | San Francisco, California | 8 | $99 |
Investigators on these documents
FEI number 3006164918 · most recent document Mar 29, 2016
About Reliable Rexall-A Compounding Pharmacy
How many FDA Form 483s has Reliable Rexall-A Compounding Pharmacy received?
FDA Intel has 1 Form 483 on file for Reliable Rexall-A Compounding Pharmacy; the most recent is dated Mar 29, 2016.
When was Reliable Rexall-A Compounding Pharmacy last inspected by FDA?
The most recent FDA inspection document on file for Reliable Rexall-A Compounding Pharmacy is a Form 483 dated Mar 29, 2016, for the site in San Francisco, California.
What did FDA cite at Reliable Rexall-A Compounding Pharmacy?
The regulations cited most in the observations on file for Reliable Rexall-A Compounding Pharmacy are 21 CFR 211.84(d)(1) (Testing and approval or rejection of components, drug product containers, and closures), 2 times; 21 CFR 211.100(a) (Written procedures; deviations), 1 time; 21 CFR 211.125(a) (Labeling issuance), 1 time.